Known targets — ChEMBL curated mechanism
HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9
The experimentally established mechanism targets of Tacedinaline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 known ✓ | Q13547 | 18/20 | 0.66 |
| ▸ | HDAC3 known ✓ | O15379 | 4/20 | 0.66 |
| ▸ | HDAC2 known ✓ | Q92769 | 4/20 | 0.66 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.66 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.58 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tacedinaline SCHEMBL144794 | 0.91 | HDAC1 (0.74) | HDAC1HDAC3HDAC2NCOR2PTGS1 | |
| Tacedinaline SCHEMBL29482198 | 0.91 | HDAC1 (0.74) | HDAC1HDAC3HDAC2NCOR2PTGS1 | |
| Tacedinaline SCHEMBL20855566 | 0.86 | HDAC1 (0.68) | HDAC1HDAC3HDAC2NCOR2MAPK1 | |
| Trifluoroacetic Acid SCHEMBL3600531 | 0.85 | HDAC1 (0.54) | HDAC1HDAC3HDAC2NCOR2PTGS1 | |
| SCHEMBL1064630 | 0.84 | HDAC1 (0.74) | HDAC1HDAC3HDAC2NCOR2PTGS1 | |
| SCHEMBL1064283 | 0.80 | HDAC1 (0.79) | HDAC1HDAC3HDAC2NCOR2 | |
| Trifluoroacetic Acid SCHEMBL20592212 | 0.79 | PTGS1 (0.53) | HDAC1HDAC3HDAC2NCOR2PTGS1 | |
| SCHEMBL8401704 | 0.78 | HDAC1 (0.89) | HDAC1HDAC3HDAC2NCOR2PTGS1 | |
| SCHEMBL15550450 | 0.78 | HDAC1 (0.72) | HDAC1HDAC3HDAC2NCOR2PTGS1 | |
| SCHEMBL1754073 | 0.78 | HDAC1 (1.00) | HDAC1HDAC3HDAC2NCOR2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266822-B2 | Solid forms of tacedinaline | THE BROAD INSTITUTE, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20140275268-A1 | NOVEL SOLID FORMS OF TACEDINALINE | THE BROAD INSTITUTE, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-8729130-B2 | Methods of using novel solid forms of tacedinaline | THE BROAD INSTITUTE, INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-20130150450-A1 | NOVEL SOLID FORMS OF TACEDINALINE | THE BROAD INSTITUTE, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130102677-A1 | NOVEL SOLID FORMS OF TACEDINALINE | THE BROAD INSTITUTE, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| WO-2012003413-A1 | NOVEL SOLID FORMS OF TACEDINALINE | THE BROAD INSTITUTE, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102677-A1 | NOVEL SOLID FORMS OF TACEDINALINE | ACSS2, SLC10A1, ACAT2 | HDAC1 101/4885HDAC3 149/4885HDAC2 250/4885 |
| US-20130150450-A1 | NOVEL SOLID FORMS OF TACEDINALINE | ACSS2, SLC10A1, ACAT2 | HDAC1 101/4885HDAC3 149/4885HDAC2 250/4885 |
| US-20140275268-A1 | NOVEL SOLID FORMS OF TACEDINALINE | ACSS2, FAM162A, ACAT2 | HDAC1 82/4885HDAC3 169/4885HDAC2 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.